At a glance
ClinicalIndex Comparison RecordN/ACompleted· 74 enrolled
Drug / intervention
escitalopram +1 moredrug
Likely dose
escitalopram 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Multi-center, Randomized, Placebo-controlled, Double-blind Clinical Trial of Escitalopram on the Progression Delaying Effect in Alzheimer's Disease
In Brief
A clinical study evaluating escitalopram and placebo for Alzheimer's Disease. Completed, enrolled 74 participants across 4 sites.
Detailed Summary
This study aimed to test whether escitalopram would slow the brain atrophy in patients with mild to moderate AD over the 52-week period.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease
CountriesSouth Korea
CollaboratorsH. Lundbeck A/S
Timeline
N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 2008
Enrollment StartNov 2008
Primary CompletionSep 2011
TodayJul 2026
First PostedJun 20, 2008
Enrollment StartNov 1, 2008
Primary CompletionSep 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 18.0 years ago
Interventions
escitalopramdrug
5 mg/day for 2 weeks, 10 mg/day for 2 weeks and 20 mg/day for 48 weeks (maintaining donepezil at the previous stable dose during the whole trial period)
placebodrug
5mg/day for 2 weeks, 10mg/day for 2 weeks and 20mg/day for 48 weeks (maintaining donepezil at the previous stable dose during the whole trial period)